Histiocytosis, Langerhans-Cell: all 81 studies
Page 1 of 1. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.
- A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsEnrolling by invitationNCT07890701Phase 1/2
- Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell HistiocytosisNot yet recruitingNCT07728201Phase 2
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisRecruitingNCT07431060Not applicable
- Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsRecruitingNCT07371182Not applicable
- Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHRecruitingNCT07187193Phase 2
- Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenRecruitingNCT07022834Phase 2
- Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsEnrolling by invitationNCT06902792Phase 1
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibRecruitingNCT06582745Phase 2
- Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell HistiocytosisRecruitingNCT06197204
- Mirdametinib in Histiocytic DisordersRecruitingNCT06153173Phase 2
- Oral Prednisone in Treating LCH of Bone in Childhood and AdolescenceRecruitingNCT06078969Phase 2
- To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHRecruitingNCT05997602Phase 2
- Histiocytic Disorder Follow-up StudyRecruitingNCT05915208
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruitingNCT05828069Phase 2
- Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell HistiocytosisNot yet recruitingNCT05477446Phase 1
- A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained ProtocolRecruitingNCT04773366Phase 3
- Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort StudyRecruitingNCT04665674
- LCH in Adults: a Collaborative, Prospective-retrospective, Observational StudyRecruitingNCT04627090
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingNCT04079179Phase 2
- Registry for Patients With Erdheim-Chester Disease and Other HistiocytosesRecruitingNCT03329274
- Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)RecruitingNCT02670707Phase 3
- Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
- Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
- Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
- Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
- Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
- Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell HistiocytosisCompletedNCT03052101Results posted
- Lenalidomide for Adult Histiocyte DisordersActive, not recruitingNCT02523040Phase 2Results posted
- Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related DisordersActive, not recruitingNCT02425904Phase 2Results posted
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
- Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell HistiocytosisTerminatedNCT00618540Phase 2Results posted
- Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCHCompletedNCT00588536Phase 2Results posted
- Stem Cell Transplant for Immunologic or Histiocytic DisordersCompletedNCT00176865Phase 2Results posted
- T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersTerminatedNCT00176826Phase 2/3Results posted
- Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHActive, not recruitingNCT07204041Phase 2
- Central China Rosai-Dorfman Disease RegistryStatus unknownNCT05284942Phase 4
- Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell HistiocytosisStatus unknownNCT05114304
- The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E MutationActive, not recruitingNCT05092815Phase 2
- Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman DiseaseSuspendedNCT05028621Not applicable
- Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile PatientsActive, not recruitingNCT04943224Phase 2
- Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT ImagingActive, not recruitingNCT04943211Phase 3
- Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisActive, not recruitingNCT04943198Phase 2
- AraC for Newly Diagnosed Adult Langerhans Cell HistiocytosisStatus unknownNCT04121819Phase 2
- Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell HistiocytosisStatus unknownNCT04120519Phase 2
- Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)Active, not recruitingNCT04100408
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
- A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E MutationStatus unknownNCT03585686Phase 2
- Denosumab for the Treatment of Adult LCHCompletedNCT03270020Phase 2
- Characterization of Pulmonary Langerhans Cell HistiocytosisStatus unknownNCT03093727
- Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell HistiocytosisCompletedNCT02665546
- Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy MeasurementCompletedNCT02608619
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS TumorsActive, not recruitingNCT02574728Phase 2
- Methotrexate and Cytosine in Adult Langerhans Cell HistiocytosisCompletedNCT02389400Phase 2
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisActive, not recruitingNCT02205762Phase 2/3
- CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationActive, not recruitingNCT01966367Phase 1/2
- Clofarabine for Langerhans in PediWithdrawnNCT01796405Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung FunctionCompletedNCT01651507
- Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell HistiocytosisStatus unknownNCT01473797Phase 2
- A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell HistiocytosisCompletedNCT01395004Phase 2
- Prospective Evaluation of Adult Pulmonary Langerhans Cell HistiocytosisCompletedNCT01225601
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell HistiocytosisWithdrawnNCT00488605Phase 3
- Cardiovascular Risk Factors and LCH in AdultsStatus unknownNCT00483925
- Combination Chemotherapy in Treating Young Patients With Langerhans Cell HistiocytosisCompletedNCT00276757Not applicable
- Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesStatus unknownNCT00084695Phase 2
- Treatment of Resistant Langerhans Cell Histiocytosis With ENBRELCompletedNCT00048373Phase 2
- Blood Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00008216
- Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic AnemiaStatus unknownNCT00008164Phase 2
- Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1